Ocumension Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Ocumension Therapeutics is forecast to grow earnings and revenue by 101.9% and 39.3% per annum respectively. EPS is expected to grow by 101.8% per annum. Return on equity is forecast to be -0.3% in 3 years.

Anahtar bilgiler

101.9%

Kazanç büyüme oranı

101.8%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi11.1%
Gelir büyüme oranı39.3%
Gelecekteki özkaynak getirisi-0.3%
Analist kapsamı

Low

Son güncelleme17 Oct 2024

Gelecekteki son büyüme güncellemeleri

Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results

Aug 15
Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results

Recent updates

With Ocumension Therapeutics (HKG:1477) It Looks Like You'll Get What You Pay For

Sep 21
With Ocumension Therapeutics (HKG:1477) It Looks Like You'll Get What You Pay For

Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results

Aug 15
Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now

Jun 13
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now

Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable

Apr 29
Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable

Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation

Mar 14
Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation

Some Analysts Just Cut Their Ocumension Therapeutics (HKG:1477) Estimates

Aug 29
Some Analysts Just Cut Their Ocumension Therapeutics (HKG:1477) Estimates

We're Hopeful That Ocumension Therapeutics (HKG:1477) Will Use Its Cash Wisely

Jul 13
We're Hopeful That Ocumension Therapeutics (HKG:1477) Will Use Its Cash Wisely

Is Ocumension Therapeutics (HKG:1477) Trading At A 48% Discount?

Jun 02
Is Ocumension Therapeutics (HKG:1477) Trading At A 48% Discount?

We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate

Jan 20
We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate

We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate

Sep 27
We're Not Very Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Rate

Could The Ocumension Therapeutics (HKG:1477) Ownership Structure Tell Us Something Useful?

Jan 23
Could The Ocumension Therapeutics (HKG:1477) Ownership Structure Tell Us Something Useful?

Kazanç ve Gelir Büyüme Tahminleri

SEHK:1477 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/20261,429271167N/A3
12/31/2025887-511042383
12/31/2024470-232-7733
6/30/2024310-323-467-175N/A
3/31/2024278-351-503-176N/A
12/31/2023246-380-540-178N/A
9/30/2023227-399-561-223N/A
6/30/2023208-418-582-269N/A
3/31/2023184-411-546-235N/A
12/31/2022159-403-511-201N/A
9/30/2022124-393-615-165N/A
6/30/202290-383-720-129N/A
3/31/202273-322-791-163N/A
12/31/202156-260-862-197N/A
9/30/202144-426-760-232N/A
6/30/202132-593-659-267N/A
3/31/202123-1,429-588-240N/A
12/31/202013-2,265-517-213N/A
9/30/20208-2,540-407-173N/A
6/30/20202-2,816-297-133N/A
3/31/20201-2,064-203-120N/A
12/31/20190-1,312-109-108N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 1477 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Kazançlar ve Piyasa: 1477 is forecast to become profitable over the next 3 years, which is considered above average market growth.

Yüksek Büyüme Kazançları: 1477 is expected to become profitable in the next 3 years.

Gelir ve Pazar: 1477's revenue (39.3% per year) is forecast to grow faster than the Hong Kong market (7.7% per year).

Yüksek Büyüme Geliri: 1477's revenue (39.3% per year) is forecast to grow faster than 20% per year.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 1477 is forecast to be unprofitable in 3 years.


Büyüyen şirketleri keşfedin